Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL-10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9, 2008, Pages 959-972

  Foley, Jason E ^a   Mariotti, Jacopo ^a   Ryan, Kaitlyn ^a   Eckhaus, Michael ^b   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

APC; GVHD; IL 2; Th2

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; GRAFT RECIPIENT; HISTOPATHOLOGY; IMMUNOMODULATION; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; SURVIVAL RATE; TH2 CELL; THERAPY EFFECT; WILD TYPE;

ACUTE DISEASE; ANIMALS; ANTIGEN-PRESENTING CELLS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 49449109282     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.06.007     Document Type: Article

References (44)

1. Fowler D.H. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 57 (2006) 225-244
2. Fowler D.H., Kurasawa K., Husebekk A., Cohen P.A., and Gress R.E. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 152 (1994) 1004-1013
3. Krenger W., Snyder K.M., Byon J.C., Falzarano G., and Ferrara J.L. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155 (1995) 585-593
4. Fowler D.H., Breglio J., Nagel G., Eckhaus M.A., and Gress R.E. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 157 (1996) 4811-4821
5. Fowler D.H., Breglio J., Nagel G., Hirose C., and Gress R.E. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 2 (1996) 118-125
6. Jung U., Foley J.E., Erdmann A.A., Eckhaus M.A., and Fowler D.H. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102 (2003) 3439-3446
7. Foley J.E., Jung U., Miera A., et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 175 (2005) 5732-5743
8. Le Gros G., Ben-Sasson S.Z., Seder R., Finkelman F.D., and Paul W.E. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 172 (1990) 921-929
9. Huang H., and Paul W.E. Impaired interleukin 4 signaling in T helper type 1 cells. J Exp Med 187 (1998) 1305-1313
10. Sad S., and Mosmann T.R. Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med 182 (1995) 1505-1515
11. Bacchetta R., Bigler M., Touraine J.L., et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179 (1994) 493-502
12. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
13. Krenger W., Snyder K., Smith S., and Ferrara J.L. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 58 (1994) 1251-1257
14. Blazar B.R., Taylor P.A., Smith S., and Vallera D.A. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 85 (1995) 842-851
15. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 66 (1998) 1220-1229
16. Hoffmann P., Ermann J., Edinger M., Fathman C.G., and Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196 (2002) 389-399
17. MacDonald K.P., Rowe V., Clouston A.D., et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 174 (2005) 1841-1850
18. Morris E.S., MacDonald K.P., Rowe V., et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 103 (2004) 3573-3581
19. Rowe V., Banovic T., MacDonald K.P., et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 108 (2006) 2485-2492
20. Min C.K., Kim B.G., Park G., Cho B., and Oh I.H. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 39 (2007) 637-645
21. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., and Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006) 28-50
22. Mekala D.J., Alli R.S., and Geiger T.L. IL-10-dependent suppression of experimental allergic encephalomyelitis by Th2-differentiated, anti-TCR redirected T lymphocytes. J Immunol 174 (2005) 3789-3797
23. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
24. Nelson B.H., Lord J.D., and Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 369 (1994) 333-336
25. Liu K., and Rosenberg S.A. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother 26 (2003) 190-201
26. Cote-Sierra J., Foucras G., Guo L., et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci USA 101 (2004) 3880-3885
27. Ferrara J.L., Marion A., McIntyre J.F., Murphy G.F., and Burakoff S.J. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 137 (1986) 1874-1877
28. Via C.S., and Finkelman F.D. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 5 (1993) 565-572
29. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95 (2000) 83-89
30. Levine B.L., Bernstein W.B., Connors M., et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 159 (1997) 5921-5930
31. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
32. Xia G., Truitt R.L., and Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 12 (2006) 397-407
33. Levine B.L., Ueda Y., Craighead N., Huang M.L., and June C.H. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 7 (1995) 891-904
34. Jung U., Foley J.E., Erdmann A.A., et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol Blood Marrow Transplant 12 (2006) 905-918
35. Kummar S., Ishii A., Yang H.K., Venzon D.J., Kim S.J., and Gress R.E. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI. Biol Blood Marrow Transplant 7 (2001) 25-30
36. Erdmann A.A., Gao Z.G., Jung U., et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105 (2005) 4707-4714
37. Jones S.C., Murphy G.F., and Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 9 (2003) 243-256
38. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
39. Thornton A.M., Donovan E.E., Piccirillo C.A., and Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172 (2004) 6519-6523
40. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202 (2005) 907-912
41. Via C.S., and Finkelman F.D. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 5 (1993) 565-572
42. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., and Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105 (2005) 2227-2234
43. Chakraverty R., and Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 110 (2007) 9-17
44. Barton B.E. STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance. Expert Opin Ther Targets 10 (2006) 459-470